Physician profile

Mujibur R Majumder

Pulmonary Disease · Brooklyn, NY

NPI 1316988165

$16,571.69

in general payments reported to CMS, 2019-2025

53 companies · $2,511 in 2025

The $2,511 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

See the full distribution for Pulmonary Disease

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$7,270.40
Education$802.92
Travel and Lodging$367.51

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Actelion Pharmaceuticals US, INC. $1,842.53 2019-2025 Uptravi, Opsumit
Glaxosmithkline, LLC. $1,776.84 2019-2025 Trelegy Ellipta, Nucala, Arexvy
Boehringer Ingelheim Pharmaceuticals, INC. $1,689.02 2019-2025 Ofev, Jascayd
Astrazeneca Pharmaceuticals LP $1,411.88 2019-2025 Fasenra, Breztri, Tezspire
Harmony Biosciences LLC $1,041.76 2020-2025 Wakix
Mallinckrodt Hospital Products INC. $915.75 2020-2025 Acthar
Insmed, INC. $751.67 2019-2025 Arikayce
Genentech USA, INC. $736.32 2019-2022
Ani Pharmaceuticals, INC. $474.95 2022-2025 Purified Cortrophin Gel
Electromed, INC. $455.05 2019-2025 Smartvest
Jazz Pharmaceuticals INC. $445.10 2019-2025
Shionogi INC $372.15 2021-2023 Fetroja
Philips North America LLC $336.73 2019-2025 Vest Therapy Und, (Ak6) Vest Therapy
Advanced Respiratory, INC $334.13 2019-2021
Inogen, INC. $307.44 2022-2024 Inogen One G5 Oxygen Concentrator - Bluetooth
Show all 52 companies
CompanyGeneral paymentsYearsTop products
Merck Sharp & Dohme LLC $304.53 2019-2025 Capvaxive, Winrevair
Mylan Specialty L.P. $260.77 2021-2024 Yupelri
Olympus Corporation of The Americas $249.07 2025
Pfizer INC. $242.61 2021-2025
Takeda Pharmaceuticals U.S.A., INC. $206.90 2022-2024 Glassia, Aralast
Amgen INC. $186.65 2022-2025 Tezspire
Regeneron Healthcare Solutions, INC. $162.85 2021-2025 Dupixent
Sunovion Pharmaceuticals INC. $157.82 2019
Mallinckrodt Enterprises LLC $149.48 2019
Abbvie INC. $149.14 2023-2025
Baxter Healthcare $140.40 2022-2024 Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System
E.R. Squibb & Sons, L.L.C. $136.85 2019-2024 Eliquis
Janssen Pharmaceuticals, INC $116.33 2020-2022
United Therapeutics Corporation $108.75 2021-2025 Tyvaso, Tyvaso
Gilead Sciences, INC. $96.01 2019
3b Medical, INC. $78.26 2025 Luna
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $75.33 2024-2025 Lifevest
Vapotherm INC $71.83 2022-2023 Vapotherm
Chiesi USA, INC. $65.97 2023-2025 Cleviprex
Biomerieux INC $65.95 2023 Nephrocheck Liquid Control Kit
Viatris Specialty LLC $65.06 2025 Yupelri
Allergan, INC. $56.05 2019-2020
Global Blood Therapeutics, INC. $53.78 2021
Verona Pharma, INC. $51.32 2025 Ohtuvayre
La Jolla Pharmaceutical Company $49.74 2019
Paratek Pharmaceuticals, INC. $47.94 2025 Nuzyra
Genzyme Corporation $43.91 2021
Novartis Pharmaceuticals Corporation $43.57 2021
Phadia US INC. $42.56 2019-2024 Immunocap
Biohaven Pharmaceuticals, INC. $37.64 2021
Circassia INC. $37.16 2019-2020
Lilly USA, LLC $25.54 2025 Zepbound
Melinta Therapeutics, LLC $24.73 2019
Bayer Healthcare Pharmaceuticals INC. $20.32 2021
Amarin Pharma, INC. $19.96 2021
Ambu INC. $18.92 2020
Astellas Pharma US INC $16.67 2020

1 company reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mujibur R Majumder

$16,571.69

in general payments reported 2019-2025

Years
2019-2025
Top company
Actelion Pharmaceuticals US, INC.
Context
The $2,511 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/150306/mujibur-r-majumder

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.